MedTrace Logo

INTERVAL - Intense Exercise Trial for Men With Metastatic Castrate-Resistant Prostate Cancer

NCT04507698 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2020-08-11

No results posted yet for this study

Summary

Exercise has been established to be safe and result in improved physical function and quality of life for most individuals with cancer. However, little information exists regarding whether exercise can increase overall survival and reduce disease progression, events related to cancer spreading to the bones (e.g. bone fracture, spinal cord compression, extra radiation or surgery), and pain in patients with metastatic prostate cancer that is no longer responding to hormone therapy. The primary objective of this study is to determine if high intensity aerobic and resistance training plus psychosocial support increases overall survival compared to psychosocial support alone in prostate cancer patients.

The Movember foundation is providing support for the conduct of this study

Conditions

Interventions

OTHER

Intensive Exercise Intervention

INTense Exercise foR surVivAL among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL - MCRPC), randomised to either the supervised exercise arm or the self-directed exercise arm.

Sponsors & Collaborators

  • Movember Foundation

    collaborator OTHER

  • Queen's University, Belfast

    collaborator OTHER

  • University of Glasgow

    collaborator OTHER

  • University of Bristol

    collaborator OTHER

  • University of Surrey

    collaborator OTHER

  • Guy's and St Thomas' NHS Foundation Trust

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-01
Primary Completion
2022-09-30
Completion
2024-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04507698 on ClinicalTrials.gov